Combined Magnetic Hyperthermia and Immune Therapy for Primary and Metastatic Tumor Treatments
Cancer immunotherapy shows promising potential in future cancer treatment but unfortunately is clinically unsatisfactory due to the low therapeutic efficacy and the possible severe immunotoxicity. Here we show a combined magnetic hyperthermia therapy (MHT) and checkpoint blockade immunotherapy for both primary tumor ablation and mimetic metastatic tumor inhibition. Monodispersed, high-performance superparamagnetic CoFe2O4MnFe2O4 nanoparticles were synthesized and used for effective MHT-induced thermal ablation of primary tumors. Simultaneously, numerous tumor-associated antigens were produced to promote the maturation and activation of dendritic cells (DCs) and cytotoxic T cells for effective immunotherapy of distant mimetic metastatic tumors in a tumor-bearing mice model. The combined MHT and checkpoint blockade immunotherapy demonstrate the great potentials in the fight against both primary and metastatic tumors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
ACS nano - 14(2020), 1 vom: 28. Jan., Seite 1033-1044 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pan, Jiong [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.12.2020 Date Revised 22.12.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acsnano.9b08550 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM305336371 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM305336371 | ||
| 003 | DE-627 | ||
| 005 | 20231225120945.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acsnano.9b08550 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1017.xml |
| 035 | |a (DE-627)NLM305336371 | ||
| 035 | |a (NLM)31935064 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pan, Jiong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combined Magnetic Hyperthermia and Immune Therapy for Primary and Metastatic Tumor Treatments |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2020 | ||
| 500 | |a Date Revised 22.12.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Cancer immunotherapy shows promising potential in future cancer treatment but unfortunately is clinically unsatisfactory due to the low therapeutic efficacy and the possible severe immunotoxicity. Here we show a combined magnetic hyperthermia therapy (MHT) and checkpoint blockade immunotherapy for both primary tumor ablation and mimetic metastatic tumor inhibition. Monodispersed, high-performance superparamagnetic CoFe2O4MnFe2O4 nanoparticles were synthesized and used for effective MHT-induced thermal ablation of primary tumors. Simultaneously, numerous tumor-associated antigens were produced to promote the maturation and activation of dendritic cells (DCs) and cytotoxic T cells for effective immunotherapy of distant mimetic metastatic tumors in a tumor-bearing mice model. The combined MHT and checkpoint blockade immunotherapy demonstrate the great potentials in the fight against both primary and metastatic tumors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a bilateral tumor model | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a checkpoint blockade immunotherapy | |
| 650 | 4 | |a core−shell structure | |
| 650 | 4 | |a magnetic hyperthermia therapy | |
| 650 | 7 | |a Ferric Compounds |2 NLM | |
| 650 | 7 | |a Manganese Compounds |2 NLM | |
| 650 | 7 | |a cobalt ferrite |2 NLM | |
| 650 | 7 | |a manganese ferrite |2 NLM | |
| 650 | 7 | |a Cobalt |2 NLM | |
| 650 | 7 | |a 3G0H8C9362 |2 NLM | |
| 700 | 1 | |a Hu, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Yuedong |e verfasserin |4 aut | |
| 700 | 1 | |a Hao, Junnian |e verfasserin |4 aut | |
| 700 | 1 | |a Ni, Dalong |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yingying |e verfasserin |4 aut | |
| 700 | 1 | |a Bao, Qunqun |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Heliang |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Chenyang |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Qingsheng |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Jianlin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ACS nano |d 2007 |g 14(2020), 1 vom: 28. Jan., Seite 1033-1044 |w (DE-627)NLM18248100X |x 1936-086X |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2020 |g number:1 |g day:28 |g month:01 |g pages:1033-1044 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acsnano.9b08550 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2020 |e 1 |b 28 |c 01 |h 1033-1044 | ||